The current review will provide an update on recent clinical research on innovative systemic therapy methods for atopic dermatitis. Until 2017, immunosuppressive medications such as cyclosporine had to be used in atopic dermatitis when topical treatments were insufficient. Several novel chemicals that particularly target inflammation in atopic dermatitis are being researched. Dupilumab was authorised in the United States and Europe in 2017 as a first-line biologic therapy for people with moderate to severe atopic dermatitis. The antibody inhibits the action of two important cytokines in type 2 polarised inflammatory responses by blocking a component of the interleukin (IL)-4 and IL-13 receptors. In addition to the dupilumab studies, full papers have been published in the last two years on the effects of anti-IL-13 (lebrikizumab, tralokinumab), anti-IL-31 receptor (nemolizumab), anti-IL-22 (fezakinumab), and small molecules targeting the histamine-4-receptor (ZPL389) and the Janus kinase inhibitor baricitinib.
In clinical studies on atopic dermatitis, a few of potential new therapeutic targets have recently been studied and reported.
